BOVNF (BioInvent International AB) Buyback Yield %: 0.00 (As of Jul. 03, 2026)


BOVNF BioInvent International AB BOVNF
50 GF Score
Price $3.29
GF Value $6.77
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Buyback Yield %?

BioInvent International AB BOVNF 50 Buyback Yield % is 0.00 as of Jul. 03, 2026. GuruFocus rates BOVNF with a GF Score™ of 50/100 and a GF Value™ of $6.77. The stock has 4 warning signs investors should review. Among 744 Biotechnology companies, BioInvent International AB ranks worse than 134408.47% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BioInvent International AB's current buyback yield was 0.00%.


BioInvent International AB Buyback Yield % Related Terms


BioInvent International AB Buyback Yield % Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Buyback Yield % Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.56 -8.83 -0.98 0.00 0.00

BioInvent International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOVNF vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, BioInvent International AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Buyback Yield % falls into.


BOVNF
50GF Score
BioInvent International AB BOVNF
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BioInvent International AB's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 216.4030344
=0.00%

BioInvent International AB's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 216.4030344
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
BioInvent International AB (BOVNF) has a Buyback Yield % of 0.00 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #999999 out of 744 companies in the Biotechnology industry.
Is BioInvent International AB's Buyback Yield % too high?
BioInvent International AB's current Buyback Yield % is 0.00. Based on the distribution chart, BioInvent International AB ranks #999999 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioInvent International AB has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #999999 out of 744 companies for Buyback Yield %. This places BioInvent International AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current Buyback Yield % of 0.00. The stock's GF Value™ is $6.77, compared to a current price of $3.29 — trading 51.4% below its estimated fair value. The current Buyback Yield % is 0.00. BioInvent International AB's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current Buyback Yield % is 0.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioInvent International AB (BOVNF) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of $3.29 is trading 51.4% below its estimated GF Value™ of $6.77.

Key valuation signals for BOVNF:

  • Buyback Yield %: 0.00
  • GF Value™: $6.77 vs. price of $3.29 (51.4% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
50GF Score

Get the complete analysis for BOVNF

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price
$6.77
GF Value